Is Basilea likely to get a buyout offer?

Shares of Basilea Pharmaceutica shot up as speculation about a possible takeover attempts heats up. Basilea recently won a $130 million arbitration award from J&J, which was held responsible for botching clinical trial work on ceftobiprole. The anti-infective was shot down by regulators in Europe and the U.S. after they determined that the data presented was unreliable. Now the biotech's low market value, pipeline of new anti-infectives and cash in the bank has made it an attractive takeover target, according to some analysts. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.